Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
By
Jeremy Veenstra-VanderWeele
28 January 2020 | 5 min read
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
By
Jeremy Veenstra-VanderWeele
10 June 2014 | 8 min read
Explore more from The Transmitter
Neuroscientists fear Trump’s DEI order may tank diversity-focused grants
Programs that prioritize diversity, equity and inclusion in the field may be at risk, leaving researchers in a “holding pattern,” according to one grant recipient.
Neuroscientists fear Trump’s DEI order may tank diversity-focused grants
Programs that prioritize diversity, equity and inclusion in the field may be at risk, leaving researchers in a “holding pattern,” according to one grant recipient.
By
Angie Voyles Askham, Claudia López Lloreda
24 January 2025 | 5 min read
Remembering the life of neuropharmacologist Floyd Bloom
The co-author of the classic textbook “The Biochemical Basis of Neuropharmacology” and pioneer in studying the roles of neurotransmitters in the brain died on 8 January at 88 years old.
Remembering the life of neuropharmacologist Floyd Bloom
The co-author of the classic textbook “The Biochemical Basis of Neuropharmacology” and pioneer in studying the roles of neurotransmitters in the brain died on 8 January at 88 years old.
By
Sydney Wyatt
24 January 2025 | 7 min read
Newly characterized striatal circuits add twist to ‘go/no-go’ model of movement control
The two novel pathways control dopamine release in opposing ways and may link motivation and mood to action, a new study shows.
Newly characterized striatal circuits add twist to ‘go/no-go’ model of movement control
The two novel pathways control dopamine release in opposing ways and may link motivation and mood to action, a new study shows.
By
Claudia López Lloreda
24 January 2025 | 4 min read